GEO DataSets

(Submitter supplied) Core binding factor (CBF) leukemias, characterized by translocations t(8;21) or inv(16)/t(16;16) targeting the core binding factor, constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, about 40% of patients relapse, and the current classification system does not fully reflect this clinical heterogeneity. Previously, gene expression profiling (GEP) revealed two distinct CBF leukemia subgroups displaying significant outcome differences and identified apoptotic signaling, MAPKinase signaling and chemotherapy-resistance mechanisms among the most significant differentially regulated pathways. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4285

Platform:

GPL570

12 Samples

Download data: CEL

Analysis of mononuclear cells isolated from untreated, CBF-AML patients representing t(8;21) and inv(16)/t(16;16) karyotypes. The CBF-AML samples exhibited differential sensitivity to treatment with ABT-737 and BV6. Results provide insight into molecular basis of sensitivity to inhibitor treatment.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 11 age, 2 disease state, 2 gender, 12 individual, 5 other, 2 tissue sets

Platform:

GPL570

Series:

GSE29883

12 Samples

Download data: CEL

(Submitter supplied) Inhibitor of apoptosis (IAP) proteins are expressed at high levels in CLL cells and may contribute to evasion of cell death leading to poor therapeutic outcome. Of note, prognostic unfavourable cases with e.g. non-mutated VH-status and TP53 mutation responded significantly better to BV6 than samples with unknown or favourable prognosis e.g. 13q deletion. The majority of cases with 17p deletion (10/12) and Fludarabine refractory cases were sensitive to BV6, indicating that BV6 acts independently of the p53 pathway. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS6083

Platform:

GPL570

12 Samples

Download data: CEL

(Submitter supplied) Apoptosis is deregulated in most, if not all, cancers, including hematological malignancies. In this study, we wanted to test whether primary acute myeloid leukemia (AML) samples are sensitive for inhibitor of apoptosis (IAP) protein antagonist treatment in vitro, and which AML subgroup might profit most from such a novel therapeutic strategy. We treated diagnostic samples of 67 adult AML patients with either cytarabine (ara-C) or IAP antagonist BV6 and correlated sensitivity with clinical, cytogenetic and molecular markers, and expression levels of selected genes involved in apoptosis. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

24 Samples

Download data: CEL

Analysis of chronic lymphocytic leukemia (CLL) cells treated with BV6, a Smac mimetic. CLL is characterized by B-lymphocyte accumulation, which is attributed to defective cell death. Inhibitor of apoptosis (IAP) proteins are highly expressed in CLL cells. Smac binds to and inhibits IAP proteins.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 agent, 4 genotype/variation, 4 individual, 2 other, 2 time sets

Platform:

GPL570

Series:

GSE62533

12 Samples

Download data: CEL

(Submitter supplied) Core binding factor (CBF) leukemias, characterized by either inv(16)/t(16;16) or t(8;21), constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, there exists substantial biological and clinical heterogeneity within these cytogenetic groups, which is not fully reflected by the current classification system. To improve the molecular characterization we profiled gene expression in a large series (n=93) of AML patients with CBF leukemia [inv(16) n=55, t(8;21) n=38]. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

8 related Platforms

93 Samples

Download data

(Submitter supplied) Recently, the p53-miR-34a network was identified to play an important role in tumorigenesis. As in acute myeloid leukemia with complex karyotype (CK-AML) TP53 alterations are the most common known molecular lesion, we further analyzed the p53-miR-34a axis in CK-AML with known TP53 status. Clinically, low miR-34a expression and TP53 alterations predicted for chemotherapy resistance and inferior outcome. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

12 Samples

Download data: CEL